TC-SP 14(compound 14)是一种口服有效的 S1P1 激动剂(EC50 = 0.042 μM),其在 S1P3 处活性极低(EC50 = 3.47 μM),可显著降低血液淋巴细胞计数并减弱对抗原挑战的迟发型超敏反应(DTH)。
产品编号: MS-Y83060 CAS No.: 1257093-40-5 分子式: C25H20F2N2O2S 分子量: 450.50
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

TC-SP 14(compound 14)是一种口服有效的 S1P1 激动剂(EC50 = 0.042 μM),其在 S1P3 处活性极低(EC50 = 3.47 μM),可显著降低血液淋巴细胞计数并减弱对抗原挑战的迟发型超敏反应(DTH)。

生物实验数据

生物活性 TC-SP 14 (compound 14) is an orally active S1P1 agonist (EC50 = 0.042 μM) with minimal activity at S1P3 (EC50 = 3.47 μM), and it significantly reduces blood lymphocyte counts and attenuates the delayed-type hypersensitivity (DTH) response to antigen challenge.
IC50 & Target S1P3 receptor:3.47 μM (EC50), S1P1 receptor:0.042 μM (EC50)
体外研究
(In Vitro)

TC-SP 14 (compound 14) neither inhibits nor induces human cytochrome P450 enzymes, is nonmutagenic, and dose not significantly inhibit the hERG channel.

体内研究
(In Vivo)

TC-SP 14 (compound 14) (0-3 mg/kg, Orally, once) produces a dose-dependent reduction in circulating blood lymphocytes 24 h postdose.
TC-SP 14 (0-3 mg/kg, Orally, daily for 10 days) significant reduces ovalbumin (OVA)-induced ear swelling.
TC-SP 14 (2-15 mg/kg, IV or PO, once) possesses acceptable characteristics.
Pharmacokinetic Parameters of TC-SP 14 in female Sprague-Dawley rats and male Cynomolgus .

species rat NHP
CL (L/h/kg) 0.33 0.50
Vss (L/kg) 3.3 1.6
T1/2 (h) 7.5 35.2
MRT (h) 10 3.3
% F 68 23

Animal Model: Lewis rats (female, n = 5/group)
Dosage: 0.3, 1.0, and 3.0 mg/kg
Administration: Orally, once
Result: Produced a dose-dependent reduction in circulating blood lymphocytes 24 h postdose, resulted in near maximal lymphopenia at 3.0 mg/kg (74% reduction in lymphocytes vs vehicle).
Animal Model: OVA-immunized Lewis rats (female, n = 8/group)
Dosage: 0.1, 0.3, 1.0, and 3.0 mg/kg
Administration: Orally, daily for 10 days
Result: Significant reduced OVA-induced ear swelling at doses of 0.3 mg/kg and higher.
Animal Model: Female Sprague-Dawley rats, Male Cynomolgus (NHP (nonhuman primates)) (n=3/group)
Dosage: 2 (IV, rat), 4 (IV, NHP), 10 (PO, NHP), 15 mg/kg (PO, rat)
Administration: IV, PO, once (Pharmacokinetic Analysis)
Result: Possessed acceptable characteristics, demonstrated low clearance, moderate steady state volumes of distribution, moderate-to-long mean residence times, and acceptable oral bioavailability.

化学信息

分子量 450.50
分子式 C25H20F2N2O2S
CAS No. 1257093-40-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础